Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Papillomavirus Infections 1Neoplasm Metastasis 1Melanoma 1Colonic Neoplasms 1Carcinoma in Situ 1Carcinoma 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9Cisplatin 6Biopsy 5Paclitaxel 4pembrolizumab 3Platinum 3Immunoglobulin G 3Disulfides 3Cetuximab 3Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3ipatasertib 2cemiplimab 2Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiosurgery 2Radiation 2Docetaxel 2Cytoreduction Surgical Procedures 2Bevacizumab 2ALT-803 2peposertib 1peginterferon alfa-2b 1interferon gamma-1b 1fludarabine phosphate 1fludarabine 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma × Indomethacin × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡